FSGS

Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis (River 3 Renal)

Protocol Name: Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis Sponsor: River 3 Renal Indication: Alport Syndrome, Focal segmental glomerulosclerosis (FSGS) Primary Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis (River 3 Renal) Read More »

ACTION3: Study of Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB (Dimerix B)

Protocol Name: ACTION3: A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB Sponsor: Dimerix B Indication: FSGS Primary Investigator: Kim Rice, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

ACTION3: Study of Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB (Dimerix B) Read More »

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glomerulosclerosis (Boehringer Ingelheim)

Protocol Name: A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glomerulosclerosis Sponsor: Boehringer Ingelheim Indication: FSGS Primary Investigator: Anupkumar Shetty, MD Location: Charlton Office, 2651 Bolton Boone Drive, DeSoto, TX 75115 DETAILS >

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glomerulosclerosis (Boehringer Ingelheim) Read More »